Ultragenyx Pharmaceutical | RARE - Current Liabilities


Ultragenyx Pharmaceutical reported $389M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 332.22M 29.22M Sep/2026
Agios Pharmaceuticals USD 77.59M 7.37M Sep/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
BioCryst Pharmaceuticals USD 195.83M 13.02M Sep/2026
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
Immunic USD 31.55M 290K Sep/2026
Insmed USD 596.57M 157.83M Sep/2026
Ionis Pharmaceuticals USD 435.29M 119.65M Sep/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Kyowa Hakko Kirin JPY 150.28B 32.11B Sep/2026
MacroGenics USD 107.23M 1.58M Sep/2026
Moderna USD 2.03B 506M Sep/2026
Neurocrine Biosciences USD 984.6M 110.1M Sep/2026
PTC Therapeutics USD 776.08M 5.01M Sep/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Sarepta Therapeutics USD 656.35M 153.44M Sep/2026
Ultragenyx Pharmaceutical USD 389M 38M Sep/2026
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026